Currently, irreversible LSD1 inhibitors based on the TCP scaffold, including TCP, GSK2879552, and ORY-1001 are undergoing clinical trials for AML (Zheng et al., 2016; Huang et al., 2017; Somervaille et al., 2016). This evidence concerns the gene SPINK1 and acute myeloid leukemia.